NCT01738139: Ipilimumab and Imatinib Mesylate in Advanced Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KIT
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 15 Years and older (Child, Adult), Senior)
Location of Metastases: 
Additional Notes: All breast cancer patients are eligible for the dose escalation phase, but only patients with a c-KIT mutation are eligible for the expansion phase
Exclusions: Patients with mutations in exon 13 V654X, 14 T6701, 17 D816X and all exon 18 mutations

Comments are closed.

Up ↑